MetaCap

MacroGenics Inc. (MGNX)

NASDAQ: MGNXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.96-0.02 (-1.01%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MGNX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$125.26M
EPS (TTM)
-$2.30
52-week range
1.32 – 5.08
Day range
1.90 – 2.08
Volume / Avg
1.52M / 747.02K
Beta
—

52-week range

$1.32$5.08

MGNX stock today

Shares of MacroGenics (MGNX) finished lower on Nov 20 at $1.96, a drop of 1.01% or $0.02 per share, versus the S&P 500's 3.70% decline. Volume was 2.0x the average at 1.52M shares, a sign of unusually heavy trading. At this level, MGNX sits near the bottom of its 52-week range of $1.32 to $5.08: 61.4% below the high, set on Jun 24, 2026 and 48.5% above the low.

MGNX is up 21.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 40.0%. MacroGenics has posted a net loss over the last twelve months (EPS of -$2.30), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About MacroGenics

Company profile

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Eric Blasius Risser
Headquarters
Rockville, MD
Employees
293
IPO year
2013

Financial highlights

Full financials

In fiscal 2025, MacroGenics generated $149.5 million in revenue, down 0.3% from fiscal 2024, its first annual decline since 2023. MacroGenics reported a net loss of $74.6 million, compared with a loss of $67.0 million a year earlier. Gross margin was 100.0% (up from 99.4%) and operating margin -48.7%.

MacroGenics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$149.50M$149.96M$58.75M$151.94M$77.45M
Growth-0.31%+155.26%-61.33%+96.19%-26.16%
Net income$-74.62M$-66.97M$-9.06M$-119.76M$-202.12M
EPS (diluted)$-1.18$-1.07$-0.15$-1.95$-3.37

Analyst forecast

Forecast

Consensus (7 analysts)

buy

Avg. price target

$8.00+308.16%

  • Strong buy 1
  • Buy 2
  • Hold 4
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $11.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.34 vs $-0.10
Surprise
-240.00%

MGNX news

All MGNX news

MacroGenics peers

Health Care sector
MGNX peer companies
CompanyPrice% ChgMarket capCompare
SIONSionna Therapeutics Inc.2.83-4.88%$127.79Mvs MGNX
MSLESatellos Bioscience Inc.5.68-2.07%$120.51Mvs MGNX
ZNTLZentalis Pharmaceuticals Inc.1.360.00%$133.64Mvs MGNX
ADAGAdagene Inc. ADR1.76-12.44%$118.17Mvs MGNX
ALXOALX Oncology Holdings Inc.1.06+3.92%$137.03Mvs MGNX
OKUROnKure Therapeutics Inc. Class A2.70-2.17%$111.21Mvs MGNX
IMUXImmunic Inc.6.99-5.41%$111.01Mvs MGNX
MENSJyong Biotech Ltd.1.45-17.14%$110.24Mvs MGNX

Indexes, lists and sector

MacroGenics stock FAQ

What is MacroGenics's stock price today?

MGNX last traded at $1.96 as of Nov 20, 4:00 PM EST, down 1.01% on the day. Prices are delayed at least 15 minutes.

Who is MacroGenics's CEO?

Mr. Eric Blasius Risser is the chief executive officer of MacroGenics Inc., which has about 293 employees.

What is the MGNX 52-week high?

The 52-week high for MGNX is $5.08 and the 52-week low is $1.32. The stock is currently 61.4% below its high.

Compare MGNX